This study focuses on patients with newly diagnosed Multiple Myeloma, a type of blood cancer affecting plasma cells, who also have severe renal impairment (kidney problems). The research evaluates a combination treatment using several medications: Isatuximab, Bortezomib, Cyclophosphamide, and Dexamethasone during the initial treatment phase, followed by maintenance therapy with Isatuximab and Lenalidomide.
The main purpose of this study is to determine how well the combination of these medications improves kidney function in patients who have both multiple myeloma and severe kidney problems. The treatment consists of two phases: first, patients receive a combination of four medications through different methods – some given by injection into a vein, some taken by mouth, and one given under the skin. After this initial phase, patients continue with maintenance treatment using two medications.
The medications work in different ways to fight the cancer cells: Isatuximab is an antibody that targets specific proteins on cancer cells, Bortezomib helps block cancer cell growth, Cyclophosphamide is a chemotherapy drug that kills cancer cells, Dexamethasone is a steroid that reduces inflammation, and Lenalidomide helps the immune system fight cancer cells. The study will last for up to 36 months for each patient.
Greece 
